Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:

Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_3774_Библиотеки_им_академика_М_И_Перельмана

.pdf
Скачиваний:
0
Добавлен:
02.09.2026
Размер:
20 Мб
Скачать
Pathophysiology andPrinciples ofManagement ofVasculitis andFibromuscular…
https://t.me/medicina_free
16
Table 16.2 1990 criteria for the classication of giant cell (temporal) arteritisa [5]
1. Age at disease onset 50years
New headache New onset of or new type of localized pain in the head
2.
3.
Temporal artery
abnormality
4. Elevated erythrocyte sedimentation rate
Abnormal artery
5. biopsy
a
For purposes of classication, a patient shall be said to have giant cell (temporal) arteritis if at
least 3 of these 5 criteria are present. The presence of any 3 or more criteria yields a sensitivity of
93.5% and a specicity of 91.2%
Fig. 16.1 Giant cell arteritis. Histological section taken from temporal artery biopsy shows marked intimal thickening with luminal stenosis associated with dense inltrate of lymphocytes, histiocytes, and eosinophils, extending to the internal elastic lamina of the media. Only very occasional giant cells are seen
Development of symptoms or ndings beginning at age 50 or older
Temporal artery tenderness to palpation or decreased pulsation, unrelated to arteriosclerosis of cervical arteries
Erythrocyte sedimentation rate50mm/h by the Westergren method
Biopsy specimen with artery showing vasculitis characterized by a predominance of mononuclear cell inltration or granulomatous inammation, usually with multinucleated giant cells
367
the yield can be improved by performing initial bilateral TAB or achieving a TAB post-xation length of at least 3cm [6].
Histologically, the inammatory inltrate in GCA is predominantly composed of histiocytes/macrophages and CD4+ lymphocytes, with variable involvement of the three arterial layers, often showing only segmental inammation in parts of the arte­rial wall (Fig.16.1). The lymphocyte population usually includes lesser numbers of CD8+ cytotoxic and CD20+ B cells. Focal fusion of histiocytes and formation of multinucleate giant cells are seen, but these are not required for the diagnosis. The inammation typically results in breaks, segmental loss and reduplication of the elas­tic lamina, best seen on elastin stain. This may lead to critical luminal narrowing and aneurysm formation. Following the active phase inammatory cell inltrates may be absent but intimal-medial scarring and injury to the elastic lamina often remains [2].
The European League Against Rheumatism (EULAR) taskforce for imaging in large vessel vasculitis guideline recommends temporal artery ultrasound as the
368
https://t.me/medicina_free
M. Rischmueller et al.
rst- line imaging modality for predominantly cranial GCA in centres where experi­ence is at hand, as the test is non-invasive, immediate and cost effective, and in some centres, is replacing the need for TAB [7]. The temporal artery ultrasound nding of a non-compressible halo sign, caused by oedema of the vessel wall, has a reported sensitivity between 77 and 79% and specicity between 96 and 100% for the diag­nosis of GCA. This investigation is dependent on training and expertise of the sonographer, however, and the ability to detect a halo sign declines rapidly after the initiation of glucocorticoids, with sensitivity falling to below 50% at 4days. For conrmation of large vessel GCA not involving cranial vessels, other imaging tech­niques are required, which are also sensitive to glucocorticoid therapy. High­resolution MRI has the advantages of the absence of radiation, the contemporaneous detection of structural lesions (such as vessel wall thickening and luminal stenosis/ occlusion), and contrast enhancement of the arterial wall presumed (but not proven) to reect active inammation [7]. Compared with TAB, 18F-uorodeoxyglucose PET combined with low dose ne cut computed tomography (18F-FDG-PET/CT) performed within 72h of commencement of glucocorticoids had a sensitivity of 92%, specicity of 85%, negative predictive value of 98%, and identied patients with aortitis, who require closer follow up for late complications such as aneurysm development or aortic regurgitation. Cranial arteritis affects temporal, vertebral, maxillary and occipital arteries, with vasculitis mimics including malignancies found in 20% of patients [8].
Treatment of GCA consists of high dose glucocorticoids, usually 40–60 mg prednisolone daily or 1mg/kg body weight, augmented by immediate intravenous pulses of high dose methylprednisolone in the presence of ocular involvement. Blindness is almost always irreversible, but is a rare occurrence after 2 weeks of high dose glucocorticoids. Glucocorticoids are slowly tapered following normalisa­tion of symptoms, CRP and ESR, usually commencing at around 4–6weeks, with ongoing monitoring of symptoms and inammatory markers. Treatment with gluco­corticoids typically continues between 18 and 24 months, with many requiring long-term therapy. When studied in the context of clinical trials, only 15–20% of patients achieve long-term remission, highlighting the need for alternative therapies.
Traditional disease modifying antirheumatic drugs (DMARDs) are not effec­tive in GCA; treatment with methotrexate (MTX) leads to a signicant, though modestly reduced risk of relapse and lower cumulative glucocorticoid doses compared with placebo, however does not reduce the rate of drug-related adverse events. Leunomide (LEF), azathioprine, cyclophosphamide (CYC), mycophe­nolate mofetil (MMF), and cyclosporin A (CyA) have not shown efcacy. Low dose aspirin is recommended to prevent thrombotic complications, but clinical evidence is lacking [9]. One year of treatment with tocilizumab (TCZ), a human­ised monoclonal antibody targeting the IL-6 receptor (IL-6R) was shown in clinical trials to be signicantly more likely to lead to sustained remission of GCA than placebo, at just over half the cumulative glucocorticoid dose [10]. Aortic MRA abnormalities resolved in only one third of patients on TCZ, how­ever, and a signicant relapse rate was observed after its cessation [11]. TCZ is
16 Pathophysiology andPrinciples ofManagement ofVasculitis andFibromuscular…
https://t.me/medicina_free
nevertheless the rst drug to be licensed by the Food and Drug Agency (FDA), the European Medicines Agency and Therapeutic Goods Administration for GCA, and has paved the way for further clinical trials. Tumour necrosis factor inhibitors (TNFi) are not effective for GCA, whereas a monoclonal antibody to the p40 subunit common to both IL-12 and IL-23 (key cytokines regulating Th1 and Th17 differentiation, respectively) showed promise for refractory GCA in an open-label prospective study. Other targets under evaluation include T cell co­stimulation, IL-1β, B cells, Janus kinases (JAK), granulocyte-macrophage col­ony-stimulating factor (GM-CSF), IL-17, and endothelin receptors. A lack of reliable biomarkers which reect vascular inammation is an impediment to individual patient management and drug development. Redirecting the focus of diagnostic and therapeutic strategies from the extravascular/systemic disease phase of the disease reected by raised CRP and ESR, to the vascular inamma­tion phase, may ultimately improve disease outcomes [3].
369
16.3.2 Takayasu Arteritis
Takayasu arteritis (TAK, previously known as “pulseless disease”) is a granuloma­tous arteritis affecting the aorta and its main branches as well as the pulmonary vasculature, causing aneurysm formation and tissue infarction. Histopathology is similar to GCA with the presence of transmural lymphocytic inltration and multi­nucleated giant cells, but involvement of cranial vessels is not a feature, and patients are typically women under 50years of age. TAK occurs across all races and geo­graphic locations, with a higher incidence in Asians and South Americans [12].
The strongest genetic susceptibility locus for TAK is HLA-B52. Non-HLA sus­ceptibility loci include Fc gamma receptor loci FCGR2A/FCGR3A, IL12B, and IL6 [13]. Early vascular lesions consist of T cells, natural killer cells, and macrophages. Granuloma formation and giant cells can subsequently be found in the media of elastic arteries. Late-stage (‘burnt out’) damage demonstrates extensive brosis and intimal hyperplasia, which may lead to aneurysm formation or arterial stenosis (Fig.16.2). In contrast to GCA, a pathogenic role for B cells has been suggested in TAK by the identication of nonspecic polyclonal hypergammaglobulinemia, cir­culating anti-endothelial antibodies, increased numbers of circulating plasmablasts, B cell inltration of aortic adventitia, and elevated serum levels of B cell-activating factor in patients with active disease [13].
Patients usually present with symptoms of limb ischaemia, hypertension and/or renal impairment. Signs on examination include differential brachial blood pres­sures, inability to palpate peripheral pulses, and subclavian, axillary, abdominal and femoral bruits. Diagnosis may be conrmed by imaging of the aortic trunk and vessels by MRI, PET or CT [7]. CRP and ESR are not always elevated. The American College of Rheumatology classication criteria for TAK are shown in Table16.3 [14].
370
ab
cd
https://t.me/medicina_free
M. Rischmueller et al.
Fig. 16.2 Takayasu arteritis. 18F-FDG-PET/CT showing increased radiotracer avidity associated with the ascending aorta (a, b). Aortic wall showing patchy lymphocytic inammatory inltrate within the media. Elsewhere there is evidence of dense brosis of the aortic wall with extensive disruption of the elastic bre architecture (c, d)
Table 16.3 1990 criteria for the classication of Takayasu arteritis
1. Age at disease onset ˂40years
2. Claudication of extremities
3. Decreased brachial
Development of symptoms or ndings related to Takayasu arteritis 40years
Development and worsening of fatigue and discomfort in muscles of one or more extremity while in use, especially the upper extremities
Decreased pulsation of 1 or both brachial arteries
a
[14]
artery pulse
BP difference
4.
Difference of >10mmHg in systolic blood pressure between arms
>10mmHg
5.
Bruit over
subclavian arteries or
Bruit audible on auscultation over 1 or both subclavian arteries or abdominal aorta
aorta
6. Arteriogram abnormality
Arteriographic narrowing or occlusion of the entire aorta, its primary branches, or large arteries in the proximal upper or lower extremities, not due to arteriosclerosis, bromuscular dysplasia, or similar causes; changes usually focal or segmental
a
For purposes of classication, a patient shall be said to have Takayasu arteritis if at least 3 of these 6 criteria are present. The presence of any 3 or more criteria yields a sensitivity of 90.5% and a specicity of 97.8%. BP = blood pressure (systolic; difference between arms).
16 Pathophysiology andPrinciples ofManagement ofVasculitis andFibromuscular…
https://t.me/medicina_free
Glucocorticoids are the mainstay of treatment for TAK. CYC is usually used initially in conjunction with high dose glucocorticoids for severe or organ-threaten­ing disease. Conventional DMARDs have shown limited potential for steroid-spar­ing in uncontrolled series [12], yet treatment with leunomide led to a favourable clinical response in 12 of 15 TAK patients with refractory disease [15]. A recent literature review reported the efcacy of TNFi (mainly iniximab, IFX), with remis­sion induction in 70–90% of TAK patients unable to achieve or maintain remission with glucocorticoids and traditional immunosuppressants alone; over 40% of these patients were able to discontinue glucocorticoids, while relapses were described in nearly 40% [15]. As in GCA, IL-6 is highly expressed within inamed arteries in TAK, and serum IL-6 levels correlate with disease activity. Several case series and case reports suggested that TCZ may be effective for relapsing or refractory TAK, but with mixed radiologic outcomes [12]. Other rare causes of aortitis, such as relapsing polychondritis and Cogan’s syndrome, have also been reported to benet from TNFi and TCZ [12]. Rituximab (RTX), a B-cell depleting monoclonal anti­body targeting CD20, may be a potentially effective and safe therapeutic option in patients with TAK refractory to the above immunosuppressive and biologic drugs, but data does not support its use as rst line biologic therapy [15].
TAK is a chronic disease and inammatory activity tends to wax and wane, with subclinical radiographic progression seen in more than two thirds of patients [12,
13], thus patients require long term monitoring and usually immunosuppression.
Stenting of arterial stenoses, particularly of renal arteries is often required, prefer­ably when vessel inammation has been controlled. Collateral circulation may compensate and improve painful limb claudication over time. In both TAK and GCA, the late complications of aortic root dilatation with aneurysm formation and/ or aortic valve regurgitation, or abdominal aortic aneurysm, may require surgical intervention. In patients with large vessel vasculitis (GCA or TAK), MRA, CT angi­ography (CTA) and/or ultrasound may be used for long-term monitoring of struc­tural damage, particularly to detect stenosis, occlusion, dilatation and/or aneurysms. The frequency of screening as well as the imaging method applied should be decided on an individual basis [
7].
371
16.4 Medium Vessel Vasculitis
16.4.1 Polyarteritis Nodosa
Polyarteritis nodosa (PAN) is a rare necrotising vasculitis affecting medium-sized or small muscular arteries. In contrast to microscopic polyangiitis (see below), PAN is not associated with glomerulonephritis or vasculitis of the small vessels (arteri­oles, capillaries and venules). PAN occurs most commonly in middle-age with a slight male predominance, with decreasing incidence concomitant with reduced prevalence of hepatitis B virus (HBV) infection.
372
https://t.me/medicina_free
The aetiopathogenesis of classic PAN is not known, and pathway(s) leading to necrotizing inammation of the blood vessels probably involve both the innate and adaptive immune systems. Newly described loss of function mutations in genes associated with autoinammatory diseases, such as CECR1 which codes for ade­nosine deaminase-2 (ADA2) can lead to a similar phenotype, implicating perturba­tion of leukocyte growth factors and endothelial instability [16]. HBV infection accounts for 30% of cases previously diagnosed with PAN; vasculitis in this setting has been shown to be caused by viral antigen-containing immune complex deposi­tion on vascular walls with complement xation and vascular damage. Cutaneous PAN is a designation given to patients presenting with necrotizing vasculitis con­ned to the skin, with occasional musculoskeletal features but no other systemic involvement [16].
The characteristic presentation of PAN is with ischaemia and infarction of numerous organs including the skin causing palpable purpura, livedo reticularis or subcutaneous nodules, nervous system causing stroke or mononeuritis, kidneys causing infarction, hypertension and renal failure, heart causing myocardial infarc­tion, pericarditis, and congestive cardiac failure, gastrointestinal system causing abdominal pain, infarction and haemorrhage, and testicles causing painful orchitis. PAN rarely affects the lungs. Systemic symptoms such as fever, weight loss, arthral­gia and myalgia are common.
Diagnosis is established by a combination of clinical features, biopsy (skin, tes­tes, renal) and/or characteristic ndings on digital subtraction angiogram, which has a better resolution than CTA.Histopathology reveals segmental transmural inam­mation of muscular arteries with evidence of necrosis and disruption of the internal and external elastic lamina. The latter can lead to aneurysmal dilation. Characteristic mesenteric or renal angiographic ndings are of multiple aneurysms and irregular constrictions of larger vessels with occlusions of smaller vessels.
Isolated cutaneous PAN often responds to low dose glucocorticoids. Higher doses of glucocorticoids are the mainstay of treatment for mild classic PAN in combination with MTX, AZA, MMF or LEF as steroid-sparing agents. CYC is used in conjunc­tion with glucocorticoids in moderate to severe cases. There is emerging evidence for iniximab for refractory cases and patients with mutations causing ADA2 deciency, and reports of benet with rituximab. Treated systemic PAN has a 5year survival rate between 75 and 80%; untreated it is usually fatal. Treatment for HBV-associated PAN is with anti-viral therapy coupled with short-term glucocorticoids, which can lead to total remission of vasculitis with no evidence of recurrence.
M. Rischmueller et al.
16.4.2 Kawasaki Disease
Kawasaki disease (KD) is a paediatric vasculitis with coronary artery aneurysms (CAA) as its main complication. It is most common in Japan and Asia, with reported incidence rates of 265/100,000, most patients being between 6months and 5years of age. The male:female ratio is approximately 1.5:1 [17].
16 Pathophysiology andPrinciples ofManagement ofVasculitis andFibromuscular…
https://t.me/medicina_free
The aetiology of KD is unknown, with current consensus being that an infectious trigger initiates an abnormal immune response involving innate and adaptive path­ways in genetically predisposed children. Several genome-wide association studies and case control studies have identied single nucleotide polymorphisms in genes which code for proteins important in immune activation including FcgRIIa, CD40, and BLK. Other identied pathways of potential importance include vascular endo­thelial growth factor (VEGF), angiopoietin, transforming growth factor-beta (TGF-β, important in T cell activation and cardiovascular remodelling), and inositol­triphosphate 3-kinase (ITPKC, part of a transmembrane signalling pathway). ITPKC inuences NLRP3 inammasome activation through intracellular calcium levels leading to an increased IL-1β and IL-18 production [17]. Multiple potential infec­tious triggers have been implicated in KD pathogenesis. In the coronary arteries, immune inltration of the arterial wall with neutrophils, CD8+ cytotoxic T cells, Ig-A producing plasma cells, and macrophages have been found, accompanied by pro-inammatory cytokines which vary in proportion and contribution over time [17].
The diagnosis of KD is based on the presence of clinical features of persistent fever in combination with a rash, cervical lymphadenopathy, non-purulent conjunc­tival injection, changes of the lips and oral cavity (including strawberry tongue, cracked lips, redness of the mucosae), and changes in extremities (swelling and redness of the palms, desquamation in the subacute phase). There is no diagnostic test for KD, and the diagnosis may be delayed or overlooked [17]. Coronary artery lesions are diagnosed by echocardiography in the acute and subacute phases. Close monitoring of CAA is important as ischemic symptoms or myocardial infarction due to thrombosis or stenosis can occur, most likely in the largest, so-called giant CAA.Apart from the presence of CAA, it is unclear whether KD causes an increased cardiovascular risk due to the vasculitis itself [17].
Treatment consists of high dose intravenous immunoglobulin (IVIg) and is directed at preventing the development of CAA.Unfortunately, 10–20% of patients fail to respond to IVIg and these children need additional treatment with a second dose of IVIg or glucocorticoids. Other immunosuppressants under investigation are inhibitors of IL-1β, TNF and calcineurin. Initial addition of high-dose aspirin is advised by the American Heart Association [
18].
373
16.5 Small Vessel Vasculitis
Small vessel vasculitides (SVV) are a group of relatively uncommon disorders characterized by inammation of small intraparenchymal arteries, arterioles, cap­illaries, and venules which leads to vascular obstruction, tissue ischemia and infarction. A complex overlapping set of clinical features involving different organs and systems may occur. According to the 2012 Chapel Hill Consensus Conference, SVV are divided into ANCA-associated vasculitides (AAV) and immune complex vasculitides (ICV) [1]. AAV are necrotizing vasculitides fre­quently associated with proteinase 3 (PR3)-ANCA or myeloperoxidase
374
https://t.me/medicina_free
(MPO)-ANCA; ICV are characterized by wall deposits of immunoglobulin and complement components, and include IgA vasculitis (IgAV), cryoglobulinaemic vasculitis (CV), anti-glomerular basement membrane disease (anti-GBM), and hypocomplementaemic urticarial vasculitis (HUV) [1].
M. Rischmueller et al.
16.5.1 Anti-neutrophil Cytoplasmic Antibody (ANCA)-
Associated Vasculitis (AAV)
ANCA are detected by indirect immunouorescence (IIF) of xed neutrophils, pro­ducing two main patterns: cytoplasmic (C-ANCA), usually caused by antibodies targeting proteinase 3 (PR3), and perinuclear (P-ANCA), the typical pattern of anti­bodies targeting myeloperoxidase (MPO). A positive C-ANCA or P-ANCA on screening IIF has low specicity and may be seen in other inammatory conditions and healthy individuals. Conrmation by enzyme-linked immunosorbent assay is required to conrm PR3 or MPO antibody specicity. There are three clinical sub­groups of AAV: granulomatosis with polyangiitis (GPA, formerly Wegener’s granu­lomatosis), eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss angiitis) and microscopic polyangiitis (MPA). These are rare and potentially life-threatening multisystem autoimmune diseases.
Environmental factors play a role in pathogenesis, supported by variation in geographical distribution, and relationship with exposure to silica, hydrocarbons and various drugs. Infections such as Staphylococcus aureus have often been noted to precede the onset or ares of AAV, with decreased relapse rates reported after use of cotrimoxazole. Genetic associations include HLA-DRB104, DPB10401, the proteinase 3 gene (PRTN3), and alpha-1-antitrypsin gene (SERPINA1) with GPA, HLA-DRB4 with EGPA, and HLA-DRB10901 with MPA.Toll-like receptor 9 (TLR 9) polymorphism is associated with PR3-ANCA but not MPO-ANCA vas­culitis. Epigenetic factors include decreased histone demethylation at PR3 and MPO loci [19]. A key role for neutrophils is indicated by amelioration of disease in mouse models in the setting of neutrophil depletion, and abnormal neutrophil extracellular traps containing PR3 and MPO have been demonstrated upon activat­ing neutrophils with ANCA derived from human sera. Macrophages also have a role in propagation of AAV [20]; the predominant effector cells implicated in EGPA are eosinophils [21].
16.5.1.1 Granulomatosis withPolyangiitis (GPA)
The range of clinical presentations is broad and includes granulomatous inam­mation of upper and lower airways and vasculitis of small and medium vessels, of which glomerulonephritis is common. Nasal symptoms include nasal obstruction, bloody nasal discharge, epistaxis, chronic sinusitis, and saddle nose deformity.
16 Pathophysiology andPrinciples ofManagement ofVasculitis andFibromuscular…
https://t.me/medicina_free
375
Subglottic stenosis, mastoiditis, otitis media, and orbital pseudotumor are seen less commonly. Systemic features such as fever, arthralgia, and malaise may be absent in the early localised phase. Pulmonary involvement occurs in up to 85% of patients ranging from asymptomatic nodules to massive haemoptysis with respiratory fail­ure. Radiologic features include pulmonary nodular inltrates, cavities, and bilat­eral ground glass opacities from pulmonary haemorrhage. Renal involvement in the form of rapidly progressive glomerulonephritis is the presenting manifestation in 20% of patients, increasing to 80% over the disease course. Ocular involvement occurs in 50% in the form of episcleritis, scleritis, and orbital disease. Cutaneous manifestations are usually minor [22].
16.5.1.2 Eosinophilic Granulomatosis withPolyangiitis (EGPA)
This syndrome is characterized by eosinophil-rich granulomatous inammation of the airways along with small- and medium-vessel vasculitis. Three different dis­ease phases are usually described, namely, prodromal, eosinophilic, and vasculitic. The main clinical feature in the prodromal stage is asthma (which may predate vasculitis by years) and allergic rhinitis with or without polyposis. Upper airway involvement is much milder than in GPA.The second phase is of peripheral and tissue eosinophilia, which may be masked by glucocorticoid use for asthma. Vasculitic manifestations occur in nerves, heart, lungs, GI tract, and kidneys. Skin involvement is a dominant feature in the form of nodules; urticaria or ulceration. Neurologic involvement occurs in 60–70% of patients in the form of multiple mononeuropathies or symmetric polyneuropathy; ischemic optic neuropathy, cra­nial neuropathies, and stroke are less common. Cardiac involvement is seen in up to 20% of patients in the form of myocarditis, pericarditis, endocarditis, valvulitis, and coronary vasculitis, and contributes to half the deaths. Renal involvement in the form of small vessel vasculitis is less common than other AAVs [22].
16.5.1.3 Microscopic Polyangiitis (MPA)
MPA is a necrotising small-vessel AAV.Initially considered a part of PAN, it was recognized as a distinct entity in 1994 [23]. The main manifestations are pauci­immune glomerulonephritis and pulmonary capillaritis. Granulomatous inamma­tion is absent. Most patients present with rapidly progressive glomerulonephritis and may be oliguric or anuric at the time of presentation, necessitating dialysis. Lung haemorrhage is the most catastrophic manifestation seen in about 10% of patients and is mostly associated with renal involvement. Most patients have consti­tutional symptoms, with fever, weight loss, arthralgia, and myalgia at the time of presentation. Neurologic involvement is common in the form of mononeuritis mul­tiplex, axonal sensorimotor neuropathy, or cranial nerve involvement. Skin manifes­tations include purpura, painful ulcers (frequently on the legs) and digital gangrene.
376
https://t.me/medicina_free
Ocular involvement includes scleritis, episcleritis, blepharitis, conjunctivitis, kerati­tis, uveitis, and retinal vasculitis [22].
Diagnosis of AAV is based on clinical features supported by positive ANCA and biopsy of the involved organ wherever feasible. EGPA is associated with MPO­ANCA in approximately 50% of cases, whereas GPA and MPA are usually associ­ated with PR3-ANCA. The presence of brinoid necrosis or crescentic glomerulonephritis is highly suggestive of AAV.
Glucocorticoids and immunosuppressive drugs used in combination are the mainstay of treatment, and have drastically changed the outcomes of these diseases, which previously had a mortality rate of 90% at 2years. Remission induction in organ- or life-threatening disease consists of CYC or RTX in combination with glu­cocorticoids. MMF was shown to be non-inferior to CYC for remission induction, but resulted in higher relapse rates [24]. The PEXIVAS randomized controlled trial, of 704 subjects demonstrated that plasma exchange does not reduce the risk of end­stage renal disease or death in patients with severe AAV treated with glucocorticoids combined with CYC or RTX induction. Compared with a standard dose, a reduced steroid regimen did not substantially increase the risk of death or end-stage renal disease and resulted in fewer serious infections [25]. Maintenance therapy following induction is individualised, options including MTX, AZA, LEF, MMF, or RTX [21].
Mepolizumab is a humanized monoclonal antibody which binds free IL-5, an essential cytokine for eosinophil development and proliferation, which is increased in active EGPA.In a randomized controlled trial, mepolizumab proved effective in prolonging remission in EGPA and allowed for reduced glucocorticoid use, leading to FDA approval in 2017 [26]. IL-5 dependent cell proliferation and survival is dependent on JAK signal transduction, as well as tyrosine kinases including Bruton tyrosine kinase (BTK). Oral inhibitors of these kinases are available, and in addi­tion, the complement component C5a is a potential therapeutic target in AAV.
M. Rischmueller et al.
16.5.2 Immune Complex Small Vessel Vasculitis
16.5.2.1 Immunoglobulin-A Vasculitis (IgAV)
Previously known as Henoch- Schönlein purpura, IgAVpredominantly affects capil­laries, venules, or arterioles, with IgA1-dominant immune complex deposition. It is the most common childhood vasculitis, affecting 10–20 children per 100,000 annu­ally. More than 90% of patients are under 10years of age, with a mean age of 6 years; adults tend to have more severe disease. Clinical presentation of IgAV comprises a characteristic tetrad of cutaneous palpable purpura, joint pain, colicky abdominal pain, and renal involvement. Proposed triggers include upper respiratory tract infections, medications, vaccinations, and (in adults) malignancies [27].
The skin rash consists of symmetric erythematous petechiae or papules on the buttocks and lower extremities, which evolve to a typical palpable purpura [28]. Gastrointestinal symptoms occur in about 50% of cases. Abdominal pain is